Introduction In patients with relapsed or refractory acute myeloid leukemia (R/R AML), FMS-like tyrosine kinase 3 (FLT3) gene mutation portends a poorer prognosis and survival. Gilteritinib, as a novel type I inhibitor, is a kind of highly selective and potent FLT3 inhibitor. It has been recommended by NCCN and ESMO guidelines for the treatment of R/R AML patients with FLT3 gene mutation. The objective of this study is to evaluate the safety and efficacy of gilteritinib-based therapy combinated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for R/R AML patients with positive FLT3-ITD mutation, and assess the impact of gilteritinib maintenance therapy on the prognosis of patients after allo-HSCT.
Methods The clinical data of 23 patients treated at the First Affiliated Hospital of Soochow University from August 2019 to January 2023, were retrospectively analyzed. We applied gilteritinib-based therapy combinated with allo-HSCT and gilteritinib maintenance after allo-HSCT. All patients received oral gilteritinib at a dose of 120mg/day, and 14 patients of them continued oral gilteritinib at a dose of 40-80 mg/day after allo-HSCT as maintenance therapy. Combination scheme including gilteritinib + venetoclax (Ven) ± azacitidine (AZA)/decitabine (DAC) (n=18), gilteritinib + Ven + DAC + Cladribine (n=1), gilteritinib + IA (idarubicin, cytarabine) (n=1) and gilteritinib + AZA + lower-dose HAAG regime (homoharringtonine, cytarabine, aclarubicin, G-CSF) (n=3). The analysis included an assessment of the composite complete remission rate (CRc), overall survival (OS), disease-free survival (DFS), and adverse events.
Results A total of 23 FLT3-ITD+ R/R AML patients were enrolled, including 12 males and 11 females, with a median age of 37 (range, 18-65) years. Eighteen cases were refractory and 5 cases were relapsed. The curative effect evaluation conducted between 14 and 21 days showed that the complete remission (CR) rate was 30.4%, the rate of CR with hematology incomplete recovery (CRi) was 56.5%, and the partial response (PR) rate was 4.3%. The CRc was 87.0%, and the minimal residual disease (MRD) negativity rate was 73.9%. The 12-month and 24-month cumulative OS rate for all patients was 91% and 79%. The median OS was not determined. The median follow-up time was 21.4 months (95% CI, 15.3-27.4).
Among the patients who responded to treatment, the 12-month and 24-month cumulative DFS rate was 91% and 78%. The median DFS time was not determined. The median OS of patients with or without gilteritinib maintenance therapy after allo-HSCT was not determined, but the OS of patients with gilteritinib maintenance therapy after allo-HSCT was longer than that of patients without gilteritinib maintenance therapy after allo-HSCT (P = 0.017). The FLT3-ITD mutation clearance rate in this study was 43.5%, and the median OS of patients with FLT3-ITD mutation clearance was significantly longer than the median OS of patients without FLT3-ITD mutation clearance (P = 0.033). The most common grade 3 and above hematological adverse events of gilteritinib-based combination therapy included leukopenia (n=17), neutropenia (n=17), febrile neutropenia (n=14), thrombocytopenia (n=15), and anemia (n=12). Gilteritinib dose was reduced to 80mg/day in 8 patients with agranulocytosis, while 5 of them stopped medication because of the occurrence of severe neutropenia (ANC < 0.5×109/L) combined with severe infections or serious adverse reactions. One patient developed differentiation syndrome during oral gilteritinib maintenance therapy after allo-HSCT, but his condition improved after treatment.
Conclusions The gilteritinib-based combination therapy demonstrates a high composite complete remission rate, MRD negativity rate, and long patients' survival in treating R/R AML patients with positive FLT3-ITD mutation. Furthermore, the clearance rate of FLT3-ITD mutation is notably high. Additionally, gilteritinib maintenance therapy after allo-HSCT has demonstrated a significant enhancement in patients' survival. It is crucial to closely monitor and manage any adverse events that may occur during treatment.
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal